EDGAR·FLOW

Corbus Pharmaceuticals Holdings, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Corbus presented CANYON-1 Phase 1b data for CRB-913, a CB1 inverse agonist, in 254 obese adults across three doses (20/40/60 mg) over 12 weeks. At 60 mg, CRB-913 achieved statistically significant 5% placebo-adjusted weight loss with dose-dependent reductions in waist circumference and BMI. Treatment discontinuation rate was 8.3%; psychiatric adverse events were infrequent and mild (no serious cases, zero suicidality); gastrointestinal AEs occurred at lower rates than published oral GLP-1 data.
Why this rating

Meaningful clinical validation of obesity asset with competitive efficacy/safety vs. GLP-1s justifies FDA engagement and Phase 2 planning. Relative to $67.8M market cap, successful obesity program could be transformational if development succeeds.

Tradability signal
NO TRADE

No trade: positive news with only -1.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$3.45 ▲ 2.12%
at our read · unknown
$3.38
+10 min · unknown
$3.38 ▲ 0.00%
+30 min · unknown
$3.32 ▼ 1.66%
+1 hr · unknown
$3.34 ▼ 1.07%
+4 hrs · unknown
$3.06 ▼ 9.51%

The stock had already moved -2.07% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ CRBP · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.